Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.

被引：0
|
作者：
Wang, Z. [1 ]
Hu, X. [1 ]
Wang, B. [1 ]
Wang, L. [1 ]
Zhang, J. [1 ]
Wang, H. [1 ]
Liu, G. [1 ]
Hu, Z. [1 ]
Wu, J. [1 ]
Shao, Z. [1 ]
机构：
[1] Fudan Univ, Shanghai Med Coll, Canc Hosp, Shanghai 200433, Peoples R China
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P5-19-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-19-06
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer: A phase III trial (CAPItello-290)
    Schmid, Peter
    Cortes, Javier
    Robson, Mark
    Iwata, Hiroji
    Hegg, Roberto
    Verma, Sunil
    Nechaeva, Marina
    Xu, Binghe
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    CANCER RESEARCH, 2020, 80 (04)
  • [32] A phase III trial of capivasertib and paclitaxel in first-line treatment of patients with metastatic triple-negative breast cancer (CAPItello290).
    Schmid, Peter
    Cortes, Javier
    Robson, Mark E.
    Iwata, Hiroji
    Hegg, Roberto
    Nechaeva, Marina
    Xu, Binghe
    Verma, Sunil
    Haddad, Vincent
    Imedio, Esteban Rodrigo
    Schiavon, Gaia
    Foxley, Andrew
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] A Phase II Trial of Gemcitabine/Carboplatin with or Without Trastuzumab in the First-Line Treatment of Patients with Metastatic Breast Cancer
    Yardley, Denise A.
    Burris, Howard. A., III
    Simons, Lisa
    Spigel, David R.
    Greco, E. Anthony
    Barton, John H.
    Shipley, Dianna
    Drosick, David
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2008, 8 (05) : 425 - 431
  • [34] Final results of first-line weekly paclitaxel plus gemcitabine in metastatic breast cancer (MBC): an AERO phase II trial
    Mousseau, M.
    Serin, D.
    Goubely-Brewer, Y.
    Petit, T.
    Priou, F.
    Zelek, L.
    BULLETIN DU CANCER, 2007, 94 (06) : 569 - 570
  • [35] Every-other-week combination of gemcitabine and docetaxel as first-line therapy in advanced breast cancer patients:: preliminary results from a phase II trial.
    Pelegri, A
    Calvo, L
    Florian, J
    Mayordomo, JI
    Vazquez, S
    Arcusa, A
    Carrasco, E
    Bayo, JL
    Martí, M
    Antón, A
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (03) : 270 - 270
  • [36] ATRACTIB: A phase II trial of first-line (1L) atezolizumab (A) in combination with paclitaxel (P) and bevacizumab (B) in metastatic triple-negative breast cancer (mTNBC)
    Cortes Salgado, A.
    Perez Garcia, J. M.
    Cortez Castedo, S. P.
    Gion Cortes, M.
    Morales Murillo, S.
    Blancas Lopez-Barajas, I.
    Blanch, S.
    Calvo Plaza, I.
    Diaz Fernandez, N.
    Marme, F.
    Martinez Bueno, A.
    Taberner Bonastre, M. T.
    De laurentiis, M.
    Ruiz Borrego, M.
    Schmid, P.
    Guarneri, V.
    Gligorov, J.
    Sampayo-Cordero, M.
    Llombart Cussac, A.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S221 - S221
  • [37] Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple Negative Breast Cancer.
    Moreno-Aspitia, A.
    Rowland, K. M.
    Liu, H.
    Hillman, D. W.
    Stella, P. J.
    Perez, E. A.
    CANCER RESEARCH, 2011, 71
  • [38] Gemcitabine and irinotecan combination in patients with metastatic bladder cancer: A phase II trial.
    Chaudhary, UB
    Sawhney, R
    Clark, H
    Keane, T
    Brescia, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 441S - 441S
  • [39] Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer
    Lobo, Christopher
    Lopes, Gilberto
    Baez, Odalys
    Castrellon, Aurelio
    Ferrell, Annapoorna
    Higgins, Connie
    Hurley, Erin
    Hurley, Judith
    Reis, Isildinha
    Richman, Stephen
    Seo, Pearl
    Silva, Orlando
    Slingerland, Joyce
    Tukia, Keleni
    Welsh, Catherine
    Glueck, Stefan
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 123 (02) : 427 - 435
  • [40] First-line Option for metastatic triple-negative Breast Cancer Live longer with new Immunotherapeutic Therapy
    Ruedesheim, Sabine M.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 69 - 69
12345